The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.89BBRL
1.25B · vs all stocks (USD)
Updated Oct 25, 2026
Revenue (TTM)
9.32BBRL
1.69B · vs all stocks (USD)
Updated Oct 25, 2026
Profit Margin
-9.60%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Beta
0.2440x
vs all stocks
Updated Oct 25, 2026
52-Week Change
250.95%
vs all stocks
Updated Oct 25, 2026
Market Capitalization
6.89BBRL
1.25B · vs all stocks (USD)
Updated Oct 25, 2026
Enterprise Value
13.63BBRL
2.48B · vs all stocks (USD)
Updated Oct 25, 2026
Forward P/E
24.17x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Price to Sales (TTM)
0.7386x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Price to Book (MRQ)
1.01x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Enterprise to Revenue
1.46x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Enterprise to EBITDA
9.22x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 6.48×.Updated Oct 25, 2026
Gross Margin
27.92%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 31.02%.Updated Oct 25, 2026
Profit Margin
-9.60%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Operating Margin
10.77%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Return on Assets (TTM)
3.53%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Return on Equity (TTM)
-12.09%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Revenue (TTM)
9.32BBRL
1.69B · vs all stocks (USD)
Updated Oct 25, 2026
Revenue per Share (TTM)
7.41BRLUpdated Oct 25, 2026
Quarterly Revenue Growth
-9.80%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Gross Profit (TTM)
2.89BBRL
525.34M · vs all stocks (USD)
Updated Oct 25, 2026
EBITDA (TTM)
2.10BBRL
381.70M · vs all stocks (USD)
Updated Oct 25, 2026
Net Income (TTM)
-892.90MBRL
-162.20M · vs all stocks (USD)
Updated Oct 25, 2026
Quarterly Earnings Growth (YoY)
-9.83%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Operating Cash Flow (TTM)
435.63MBRL
79.13M · vs all stocks (USD)
Updated Oct 25, 2026
Levered Free Cash Flow (TTM)
489.76MBRL
88.96M · vs all stocks (USD)
Updated Oct 25, 2026
5-Year Average Dividend Yield
0.79%
vs all stocks
Updated Oct 25, 2026
Payout Ratio
2360.42%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Minority Interest (Equity)
27.89MBRLFY2025 · Dec 31, 2025
Revenue
11.17BBRLFY2025 · Dec 31, 2025
Cost of Goods Sold
7.78BBRLFY2025 · Dec 31, 2025
Gross Profit
3.39BBRLFY2025 · Dec 31, 2025
Operating Income
1.01BBRL
183.88M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-612.76MBRLFY2025 · Dec 31, 2025
Income Tax Expense
521.96MBRLFY2025 · Dec 31, 2025
Net Income
-1.14BBRLFY2025 · Dec 31, 2025
EBIT
915.24MBRLFY2025 · Dec 31, 2025
EBITDA (Income Statement)
2.10BBRLFY2025 · Dec 31, 2025
Selling, General & Administrative
2.38BBRLFY2025 · Dec 31, 2025
Non-operating Interest Income
260.17MBRLFY2025 · Dec 31, 2025
Non-operating Interest Expense
1.53BBRLFY2025 · Dec 31, 2025
EPS (Basic)
-0.9218BRLFY2025 · Dec 31, 2025
EPS (Diluted)
-0.9218BRLFY2025 · Dec 31, 2025
Basic Shares Outstanding
1.25BSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
1.25BSharesFY2025 · Dec 31, 2025
Minority Interests (P&L)
-16.96MBRLFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00BRLFY2025 · Dec 31, 2025
Operating Cash Flow
594.53MBRLFY2025 · Dec 31, 2025
Free Cash Flow
329.33MBRLFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
2.67BBRLFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-612.76MBRLFY2025 · Dec 31, 2025
Stock-based Compensation
21.05MBRLFY2025 · Dec 31, 2025
Other Non-cash Items
1.76BBRLFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-661.58MBRLFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
91.70MBRLFY2025 · Dec 31, 2025
Capital Expenditures
-265.20MBRLFY2025 · Dec 31, 2025
Net Intangibles (CF)
-19.90MBRLFY2025 · Dec 31, 2025
Net Acquisitions
1.66BBRLFY2025 · Dec 31, 2025
Purchase of Investments
-79.17MBRLFY2025 · Dec 31, 2025
Sale of Investments
129.95MBRLFY2025 · Dec 31, 2025
Other Investing Activity
-76.92MBRLFY2025 · Dec 31, 2025
Net Investing Cash Flow
1.37BBRLFY2025 · Dec 31, 2025
Long-term Debt Issuance
4.35BBRLFY2025 · Dec 31, 2025
Long-term Debt Payments
-4.19BBRLFY2025 · Dec 31, 2025
Common Dividends Paid
-5.02MBRLFY2025 · Dec 31, 2025
Other Financing Charges
-334.73MBRLFY2025 · Dec 31, 2025
Net Financing Cash Flow
-175.08MBRLFY2025 · Dec 31, 2025
Shares Outstanding
1.25BSharesUpdated Oct 25, 2026
Float Shares
1.18BSharesUpdated Oct 25, 2026
% Held by Insiders
5.94%
vs all stocks
Updated Oct 25, 2026
% Held by Institutions
87.00%
vs all stocks
Updated Oct 25, 2026
Total Cash (MRQ)
958.70MBRL
174.15M · vs all stocks (USD)
Updated Oct 25, 2026
Total Cash per Share (MRQ)
0.7670BRLUpdated Oct 25, 2026
Total Debt (MRQ)
7.67BBRL
1.39B · vs all stocks (USD)
Updated Oct 25, 2026
Total Debt to Equity (MRQ)
1.12x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Current Ratio (MRQ)
1.27x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Book Value per Share (MRQ)
5.47BRLUpdated Oct 25, 2026
Total Assets
18.56BBRL
3.37B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
5.65BBRLFY2025 · Dec 31, 2025
Total Liabilities
11.67BBRLFY2025 · Dec 31, 2025
Total Non-current Assets
12.91BBRLFY2025 · Dec 31, 2025
Total Non-current Liabilities
7.11BBRLFY2025 · Dec 31, 2025
Total Current Liabilities
4.56BBRLFY2025 · Dec 31, 2025
Cash
149.41MBRLFY2025 · Dec 31, 2025
Cash Equivalents
2.52BBRLFY2025 · Dec 31, 2025
Cash & Cash Equivalents
2.67BBRLFY2025 · Dec 31, 2025
Accounts Receivable
2.10BBRLFY2025 · Dec 31, 2025
Inventory
190.37MBRLFY2025 · Dec 31, 2025
Accounts Payable
866.24MBRLFY2025 · Dec 31, 2025
Short-term Debt
2.36BBRLFY2025 · Dec 31, 2025
Long-term Debt
6.49BBRLFY2025 · Dec 31, 2025
Common Stock (Book)
19.54BBRLFY2025 · Dec 31, 2025
Retained Earnings
-4.03BBRLFY2025 · Dec 31, 2025
Total Shareholders' Equity
6.89BBRL
1.25B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
79.14MBRLFY2025 · Dec 31, 2025
52-Week Low
1.39BRLUpdated Oct 25, 2026
52-Week High
5.79BRLUpdated Oct 25, 2026
52-Week Change
250.95%
vs all stocks
Updated Oct 25, 2026
Beta
0.2440x
vs all stocks
Updated Oct 25, 2026
50-Day MA
3.47BRLUpdated Oct 25, 2026
200-Day MA
3.33BRLUpdated Oct 25, 2026
Avg 10-Day Volume
1.68MSharesUpdated Oct 25, 2026
Avg 30-Day Volume
1.54MSharesUpdated Oct 25, 2026
Diluted EPS (TTM)
-0.7100BRLUpdated Oct 25, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.01×, lower than 95% of its Diagnostics & Research peers (median 3.03×)Notable